Apnimed (NASDAQ:APMD) soars 56% as FDA decision could push sleep-apnea valuation close to $1 billion
Apnimed Inc. finished its first session on Nasdaq at $25, representing a 56.25% increase from its IPO price of $16. Market data indicated a market capitalization close to $950 million. The regular session had ended, but after-hours trading was still ongoing. The stock was last quoted at $23, reflecting an 8% drop from the closing price.
